concept,name,concept_type
age_group,Age group (in years),entity_domain
country,Country or territory name,entity_domain
risk_factor,Cases attributable to a specific risk factor,entity_domain
sex,Sex,entity_domain
agegroup_option,The set of age groups by which notifications have been disaggregated,measure
all_conf_xdr,Number of laboratory-confirmed XDR-TB cases identified in the current year (including in MDR cases diagnosed in previous years).,measure
annual_report_published,Does the National TB Programme (or equivalent) produce a publicly available annual report about the status of the TB epidemic and progress in response efforts?,measure
best,Best estimate,measure
bmu,Number of TB Basic Management Units in the country,measure
bmu_community_impl,Number of TB Basic Management Units which implemented community-based referrals or any form of community treatment adherence support,measure
bmu_ref_data,Number of Basic Management Units with data on referrals by community health workers / community volunteers,measure
bmu_rxsupport_data,Number of Basic Management Units with data on community treatment adherence support,measure
bmu_rxsupport_data_coh,Total number of patients who started TB treatment in the Basic Management Units with data on community treatment adherence support,measure
budget_cpp_dstb,"Average cost of drugs budgeted per patient for drug-susceptible TB treatment, excluding buffer stock (US Dollars)",measure
budget_cpp_mdr,"Average cost of drugs budgeted per patient for MDR-TB treatment, excluding buffer stock (US Dollars)",measure
budget_cpp_tpt,"Average cost of drugs budgeted per patient for  TB preventive treatment, excluding buffer stock (US Dollars)",measure
budget_cpp_xdr,"Average cost of drugs budgeted per patient for pre-XDR/XDR-TB treatment, excluding buffer stock (US Dollars)",measure
budget_fld,Budget required for drugs to treat drug-susceptible TB (US Dollars),measure
budget_lab,"Budget required for laboratory infrastructure, equipment and supplies (US Dollars)",measure
budget_mdrmgt,Budget required for programme costs to treat drug-resistant TB (US Dollars),measure
budget_orsrvy,Budget required for operational research and surveys (US Dollars),measure
budget_oth,Budget required for all other budget line items (US Dollars),measure
budget_patsup,Budget required for patient support (US Dollars),measure
budget_prog,Budget required for programme costs to treat drug-susceptible TB (US Dollars),measure
budget_sld,Budget required for drugs to treat drug-resistant TB (US Dollars),measure
budget_staff,Budget required for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars),measure
budget_tbhiv,Budget required for collaborative TB/HIV activities (US Dollars),measure
budget_tot,Total budget required (US Dollars),measure
budget_tpt,Budget required for TB preventive treatment: drugs (US Dollars),measure
c_cdr,"Case detection rate (all forms) [also known as TB treatment coverage], percent",measure
c_cdr_hi,"Case detection rate (all forms) [also known as TB treatment coverage], percent, high bound",measure
c_cdr_lo,"Case detection rate (all forms) [also known as TB treatment coverage], percent, low bound",measure
c_new_snep_tsr,"Treatment success rate for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases, percent  (not used after 2011)",measure
c_new_sp_tsr,"Treatment success rate for new pulmonary smear-positive (and/or culture-positive) cases, percent  (not used after 2011)",measure
c_new_tsr,"Treatment success rate for all new cases (including relapse cases if rel_with_new_flg = 1), percent",measure
c_newinc,Total of new and relapse cases and cases with unknown previous TB treatment history,measure
c_newinc_100k,"Case notification rate, which is the total of new and relapse cases and cases with unknown previous TB treatment history per 100 000 population (calculated)",measure
c_ret_tsr,"Treatment success rate for re-treatment cases (excluding relapse cases if rel_with_new_flg = 1), percent",measure
c_tbhiv_tsr,"Treatment success rate for HIV-positive TB cases, percent",measure
caseb_err_nat,Did the National Tuberculosis Programme keep (or have access to) an electronic case-based database for TB patients on treatment at national level,measure
cash_trans,(if social_protn=1) Are there conditional and/or unconditional cash-transfers?,measure
cf_community,"Expected funding for community engagement activities, in US Dollars",measure
cf_fld,Expected funding for drugs to treat drug-susceptible TB (US Dollars),measure
cf_lab,"Expected funding for laboratory infrastructure, equipment and supplies (US Dollars)",measure
cf_mdrmgt,Expected funding for programme costs to treat drug-resistant TB (US Dollars),measure
cf_orsrvy,Expected funding for operational research and surveys (US Dollars),measure
cf_oth,Expected funding for all other budget line items (US Dollars),measure
cf_patsup,Expected funding for patient support (US Dollars),measure
cf_prog,Expected funding for programme costs to treat drug-susceptible TB (US Dollars),measure
cf_sld,Expected funding for drugs to treat drug-resistant TB (US Dollars),measure
cf_staff,Expected funding for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars),measure
cf_tbhiv,Expected funding for collaborative TB/HIV activities (US Dollars),measure
cf_tot,Total expected funding for all budget line items (US Dollars),measure
cf_tot_domestic,"Expected funding from domestic sources, including loans (US Dollars)",measure
cf_tot_gf,"Expected funding from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)",measure
cf_tot_grnt,Expected funding from other sources (US Dollars),measure
cf_tot_usaid,Expected funding from USAID (US Dollars),measure
cf_tpt,Expected funding for TB preventive treatment drugs (US Dollars),measure
cfr,Estimated TB case fatality ratio,measure
cfr_hi,Estimated TB case fatality ratio: high bound,measure
cfr_lo,Estimated TB case fatality ratio: low bound,measure
cfr_pct,Estimated TB case fatality ratio expressed as a percentage,measure
cfr_pct_hi,Estimated TB case fatality ratio: high bound expressed as a percentage,measure
cfr_pct_lo,Estimated TB case fatality ratio: low bound expressed as a percentage,measure
coh,Outcomes: cohort size,measure
cohort_type,Cohort type,measure
collab_private_lab,Were any non-NTP laboratories in the private sector (including NGOs) collaborating with the NTP?,measure
collab_public_lab,Were any non-NTP laboratories in the public sector collaborating with the NTP?,measure
community_annual_report,Did representatives of communities affected by TB or civil society have a formal role in the development of the national annual TB report,measure
community_budget_available,Are data available on the funding committed to community engagement activities in the national TB budget?,measure
community_data_available,Are data available on community-based referrals or any form of community treatment adherence support?,measure
community_manuals,Did representatives of communities affected by TB or civil society have a formal role in the development or update of national TB guidelines or manuals,measure
community_nsp,Did representatives of communities affected by TB or civil society have a formal role in the development of the national strategic plan,measure
community_prog_review,Did representatives of communities affected by TB or civil society have a formal role in the preparation and conduct of the TB programme review,measure
conf_mdr,Number of laboratory-confirmed MDR-TB cases identified,measure
conf_mdr_tx,Number of laboratory-confirmed MDR-TB patients who started treatment for MDR-TB,measure
conf_rr_fqr,Number of laboratory-confirmed TB cases that are resistant to rifampicin and resistant to any fluoroquinolone (pre-XDR-TB or XDR-TB),measure
conf_rr_fqr_tx,Number of patients with laboratory-confirmed resistance to rifampicin and resistance to any fluoroquinolone (i.e. with pre-XDR-TB or XDR-TB) who started treatment for pre-XDR-TB or XDR-TB.,measure
conf_rr_nfqr,Number of laboratory-confirmed TB cases with rifampicin resistance and with no known resistance to any fluoroquinolones,measure
conf_rr_nfqr_tx,Number of patients with laboratory-confirmed resistance to rifampicin and with no known resistance to any fluoroquinolones who started treatment for MDR-TB. (This does not include patients treated for pre-XDR-TB or XDR-TB).,measure
conf_rrmdr,Number of laboratory-confirmed RR-TB or MDR-TB cases identified,measure
conf_rrmdr_tx,Number of laboratory-confirmed rifampicin-resistant (RR-TB) or multidrug-resistant TB (MDR-TB) patients who started treatment for MDR-TB,measure
conf_xdr_tx,Number of laboratory-confirmed XDR-TB patients who started treatment for XDR-TB,measure
culture,Number of sites providing TB diagnostic services using culture at the end of the reporting year,measure
culture_eqa_pass,Number of sites providing TB diagnostic services using culture that demonstrated proficiency by panel testing in the reporting year,measure
died,Outcomes: died,measure
disagg_zoonotic,(if ident_zoonotic=1) Are numbers of people diagnosed with zoonotic TB available disaggregated by subspecies?,measure
district,Total number of districts,measure
district_cxr,Number of districts in which chest X-ray was used regularly (with or without CAD) for TB screening (chest X-ray screening every week of the year or at least in quarterly active case-finding campaigns),measure
district_description,"The name used in the country for the administrative level often known as a «district», a «basic management unit» or a «county».",measure
district_monitor_pos_rate,Number of districts that monitored test positivity rate,measure
district_wrd,Number of districts in which all facilities have a TB diagnostic algorithm that requires a WHO-recommended rapid diagnostic test to be used as the initial diagnostic test for all individuals with presumptive TB,measure
dst,Number of sites providing phenotypic drug susceptibility testing for first-line drugs only at the end of the reporting year,measure
dst_bdq,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for bedaquiline at the end of the reporting year,measure
dst_bdq_eqa_pass,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for bedaquiline that demonstrated proficiency by panel testing in the reporting year,measure
dst_eqa_pass,Number of sites providing phenotypic drug susceptibility testing for first-line drugs only that demonstrated proficiency by panel testing,measure
dst_inh,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for isoniazid at the end of the reporting year,measure
dst_inh_eqa_pass,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for isoniazid that demonstrated proficiency by panel testing in the reporting year,measure
dst_lzd,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for linezolid at the end of the reporting year,measure
dst_lzd_eqa_pass,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for linezolid that demonstrated proficiency by panel testing in the reporting year,measure
dst_moxlev,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for moxifloxacin and/or levofloxacin at the end of the reporting year,measure
dst_moxlev_eqa_pass,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for moxifloxacin and/or levofloxacin that demonstrated proficiency by panel testing in the reporting year,measure
dst_naat_pza,Number of sites providing TB diagnostic services using drug susceptibility testing for pyrazinamide at the end of the reporting year,measure
dst_pza,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for pyrazinamide at the end of the reporting year,measure
dst_pza_eqa_pass,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for pyrazinamide that demonstrated proficiency by panel testing in the reporting year,measure
dst_rif,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for rifampicin at the end of the reporting year,measure
dst_rif_eqa_pass,Number of sites providing TB diagnostic services using phenotypic drug susceptibility testing for rifampicin that demonstrated proficiency by panel testing in the reporting year,measure
dst_rlt_hr_new,Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to isoniazid (regardless of result for rifampicin),measure
dst_rlt_hr_ret,Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to isoniazid (regardless of result for rifampicin),measure
dst_rlt_new,Drug resistance surveillance: Among new pulmonary TB patients with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicin,measure
dst_rlt_ret,Drug resistance surveillance: Among patients previously treated for TB with positive identification for M. Tuberculosis complex (confirmed by culture and/or line-probe assay): number of patients with available drug susceptibility testing results for isoniazid and rifampicin,measure
dst_rlt_rr_new,Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid),measure
dst_rlt_rr_ret,Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin and isoniazid and with resistance to rifampicin (regardless of result for isoniazid),measure
dx_test_sites,Total number of sites providing laboratory diagnostic testing for TB at the end of the reporting year,measure
e_hh_contacts,Estimated number of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease,measure
e_hh_contacts_hi,Estimated number of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease: High bound,measure
e_hh_contacts_lo,Estimated number of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease: Low bound,measure
e_hh_size,Estimated average household size,measure
e_inc_100k,Estimated incidence (all forms) per 100 000 population,measure
e_inc_100k_hi,"Estimated incidence (all forms) per 100 000 population, high bound",measure
e_inc_100k_lo,"Estimated incidence (all forms) per 100 000 population, low bound",measure
e_inc_num,Estimated number of incident cases (all forms),measure
e_inc_num_hi,"Estimated number of incident cases (all forms), high bound",measure
e_inc_num_lo,"Estimated number of incident cases (all forms), low bound",measure
e_inc_rr_num,Estimated incidence of rifampicin resistant TB (absolute number),measure
e_inc_rr_num_hi,Estimated incidence of rifampicin resistant TB (absolute number): high bound,measure
e_inc_rr_num_lo,Estimated incidence of rifampicin resistant TB (absolute number): low bound,measure
e_inc_tbhiv_100k,Estimated incidence of TB cases who are HIV-positive per 100 000 population,measure
e_inc_tbhiv_100k_hi,"Estimated incidence of TB cases who are HIV-positive per 100 000 population, high bound",measure
e_inc_tbhiv_100k_lo,"Estimated incidence of TB cases who are HIV-positive per 100 000 population, low bound",measure
e_inc_tbhiv_num,Estimated incidence of TB cases who are HIV-positive,measure
e_inc_tbhiv_num_hi,"Estimated incidence of TB cases who are HIV-positive, high bound",measure
e_inc_tbhiv_num_lo,"Estimated incidence of TB cases who are HIV-positive, low bound",measure
e_mort_100k,Estimated mortality of TB cases (all forms) per 100 000 population,measure
e_mort_100k_hi,"Estimated mortality of TB cases (all forms) per 100 000 population, high bound",measure
e_mort_100k_lo,"Estimated mortality of TB cases (all forms) per 100 000 population, low bound",measure
e_mort_exc_tbhiv_100k,"Estimated mortality of TB cases (all forms, excluding HIV) per 100 000 population",measure
e_mort_exc_tbhiv_100k_hi,"Estimated mortality of TB cases (all forms, excluding HIV), per 100 000 population, high bound",measure
e_mort_exc_tbhiv_100k_lo,"Estimated mortality of TB cases (all forms, excluding HIV), per 100 000 population, low bound",measure
e_mort_exc_tbhiv_num,"Estimated number of deaths from TB (all forms, excluding HIV)",measure
e_mort_exc_tbhiv_num_hi,"Estimated number of deaths from TB (all forms, excluding HIV), high bound",measure
e_mort_exc_tbhiv_num_lo,"Estimated number of deaths from TB (all forms, excluding HIV), low bound",measure
e_mort_num,Estimated number of deaths from TB (all forms),measure
e_mort_num_hi,"Estimated number of deaths from TB (all forms), high bound",measure
e_mort_num_lo,"Estimated number of deaths from TB (all forms), low bound",measure
e_mort_tbhiv_100k,"Estimated mortality of TB cases who are HIV-positive, per 100 000 population",measure
e_mort_tbhiv_100k_hi,"Estimated mortality of TB cases who are HIV-positive, per 100 000 population, high bound",measure
e_mort_tbhiv_100k_lo,"Estimated mortality of TB cases who are HIV-positive, per 100 000 population, low bound",measure
e_mort_tbhiv_num,Estimated number of deaths from TB in people who are HIV-positive,measure
e_mort_tbhiv_num_hi,"Estimated number of deaths from TB in people who are HIV-positive, high bound",measure
e_mort_tbhiv_num_lo,"Estimated number of deaths from TB in people who are HIV-positive, low bound",measure
e_pop_num,Estimated total population number,measure
e_prevtx_eligible,Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy,measure
e_prevtx_eligible_hi,Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy: high bound,measure
e_prevtx_eligible_lo,Estimated number of children aged under 5 who are household contacts of TB cases who are eligible for TB preventive therapy: low bound,measure
e_prevtx_hh_contacts_pct,Estimated % of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease who were provided with TB preventive treatment,measure
e_prevtx_hh_contacts_pct_hi,Estimated % of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease who were provided with TB preventive treatment: High bound,measure
e_prevtx_hh_contacts_pct_lo,Estimated % of household contacts of people newly diagnosed with bacteriologically confirmed pulmonary TB disease who were provided with TB preventive treatment: Low bound,measure
e_prevtx_kids_pct,Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy,measure
e_prevtx_kids_pct_hi,Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy: High bound,measure
e_prevtx_kids_pct_lo,Estimated % of children received TB preventive therapy aged under 5 who are household contacts of TB cases and who are eligible for TB preventive therapy: Low bound,measure
e_rr_in_notified_labconf_pulm,Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases,measure
e_rr_in_notified_labconf_pulm_hi,Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases: high bound,measure
e_rr_in_notified_labconf_pulm_lo,Estimated number of RR-TB cases among notified bacteriologically confirmed pulmonary TB cases: low bound,measure
e_rr_pct_new,Estimated percentage of new TB cases with rifampicin resistant TB,measure
e_rr_pct_new_hi,Estimated percentage of new TB cases with rifampicin resistant TB: high bound,measure
e_rr_pct_new_lo,Estimated percentage of new TB cases with rifampicin resistant TB: low bound,measure
e_rr_pct_ret,Estimated percentage of previously treated TB cases with rifampicin resistant TB,measure
e_rr_pct_ret_hi,Estimated percentage of previously treated TB cases with rifampicin resistant TB: high bound,measure
e_rr_pct_ret_lo,Estimated percentage of previously treated TB cases with rifampicin resistant TB: low bound,measure
e_tbhiv_prct,Estimated HIV in incident TB (percent),measure
e_tbhiv_prct_hi,"Estimated HIV in incident TB (percent), high bound",measure
e_tbhiv_prct_lo,"Estimated HIV in incident TB (percent), low bound",measure
enable_tx_adherence,(if social_protn=1) Are there enablers to adhere to TB treatment?,measure
ep_spec_available,Are data available on the number of bacteriologically confirmed extrapulmonary TB cases with test results for the speciation of the Mycobacterium tuberculosis complex in the reporting year?,measure
exp_cpp_dstb,"Average cost of drugs spent per patient starting first-line TB treatment, excluding buffer stock (US Dollars)",measure
exp_cpp_mdr,"Average cost of drugs spent per patient starting second-line treatment for MDR-TB, excluding buffer stock (US Dollars)",measure
exp_cpp_tpt,"Average cost of drugs spent per person starting TB preventive treatment, excluding buffer stock (US Dollars)",measure
exp_cpp_xdr,"Average cost of drugs spent per patient starting pre-XDR/XDR-TB treatment, excluding buffer stock (US Dollars)",measure
exp_fld,Actual expenditure on drugs to treat drug-susceptible TB (US Dollars),measure
exp_lab,"Actual expenditure on laboratory infrastructure, equipment and supplies (US Dollars)",measure
exp_mdrmgt,Actual expenditure on programme costs to treat drug-resistant TB (US Dollars),measure
exp_orsrvy,Actual expenditure on operational research and surveys (US Dollars),measure
exp_oth,Actual expenditure on all other budget line items (US Dollars),measure
exp_patsup,Actual expenditure on patient support (US Dollars),measure
exp_prog,Actual expenditure on programme costs to treat drug-susceptible TB (US Dollars),measure
exp_sld,Actual expenditure on drugs to treat drug-resistant TB (US Dollars),measure
exp_staff,Actual expenditure on National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars),measure
exp_tbhiv,Actual expenditure on collaborative TB/HIV activities (US Dollars),measure
exp_tot,Total actual expenditure (US Dollars),measure
exp_tpt,Actual expenditure on drugs for TB preventive treatment (US Dollars),measure
fail,Outcomes: treatment failed,measure
food_security,(if social_protn=1) Are there measures to ensure food security?,measure
free_access_tbdx,(if social_protn=1) Is there free access to TB diagnostic testing (including all WHO-recommended rapid diagnostics  chest x-rays  culture or smear microscopy) for people with signs or symptoms presumptive of TB?,measure
free_access_tbtx,(if social_protn=1) Is there free access to TB treatment and related medical services?,measure
g_whoregion,WHO region,measure
gov_funding_cash_trans,(if cash_trans=1) Does funding for conditional and/or unconditional cash-transfers include funding from the government?,measure
gov_funding_tx_enablers,(if enable_tx_adherence=1) Does funding for enablers to adhere to TB treatment include funding from the government?,measure
hcfvisit_dstb,Typical number of visits to a health facility after diagnosis for patients starting first-line TB treatment,measure
hcfvisit_mdr,Typical number of visits to a health facility after diagnosis for patients starting MDR-TB/XDR-TB treatment,measure
hcw_tb_infected,Number of health-care workers who had TB,measure
hcw_tot,Total number of health-care workers who were working in the country in the public and private sector,measure
hi,High bound of estimate,measure
hiv_all,Total number of people who are on antiretroviral therapy,measure
hiv_all_tpt,Total number of people who are on antiretroviral therapy and who started TB preventive treatment,measure
hiv_all_tpt_completed,Number of people on antiretroviral therapy who completed TB preventive treatment (TPT) among those who initiated any course of TPT,measure
hiv_all_tpt_started,Number of people on antiretroviral therapy who initiated any course of TB preventive treatment,measure
hiv_art,HIV-positive TB patients started or continued on antiretroviral therapy (ART),measure
hiv_cpt,HIV-positive TB patients started or continued on co-trimoxazole preventive therapy (CPT),measure
hiv_elig_all,Total number of people who are on antiretroviral therapy and who are eligible for TB preventive treatment (TPT),measure
hiv_elig_all_tpt,Total number of people who are on antiretroviral therapy and eligible for TB preventive treatment (TPT) who started TPT,measure
hiv_elig_new,Total number of people who started antiretroviral therapy in the last 12 months and who are eligible for TB preventive treatment (TPT),measure
hiv_elig_new_tpt,Total number of people who started antiretroviral therapy in the last 12 months and eligible for TB preventive treatment (TPT) who started TPT,measure
hiv_ipt,People living with HIV newly enrolled in HIV treatment who started treatment for latent TB infection,measure
hiv_ipt_reg_all,People living with HIV currently enrolled in HIV treatment who started treatment for latent TB infection,measure
hiv_new,Total number of people who started antiretroviral therapy in the last 12 months,measure
hiv_new_snep_cmplt,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: completed  (not used after 2011),measure
hiv_new_snep_coh,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: cohort size  (not used after 2011),measure
hiv_new_snep_def,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: defaulted  (not used after 2011),measure
hiv_new_snep_died,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: died  (not used after 2011),measure
hiv_new_snep_fail,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done HIV-positive TB cases: failed (not used after 2011),measure
hiv_new_sp_cmplt,Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: completed (not used after 2011),measure
hiv_new_sp_coh,Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: cohort size (not used after 2011),measure
hiv_new_sp_cur,Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: cured (not used after 2011),measure
hiv_new_sp_def,Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: defaulted (not used after 2011),measure
hiv_new_sp_died,Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: died (not used after 2011),measure
hiv_new_sp_fail,Outcomes for new pulmonary smear-positive (and/or culture-positive) HIV-positive TB cases: failed (not used after 2011),measure
hiv_new_tpt,Total number of people who started antiretroviral therapy in the last 12 months and who started TB preventive treatment,measure
hiv_reg,Total number of people registered as HIV-positive regardless of year of diagnosis. (Total number of adults and children enrolled in HIV care; includes everyone in the HIV care and/or ART register),measure
hiv_reg_all,Number of adults and children currently enrolled in HIV treatment during the year.,measure
hiv_reg_new,Number of adults and children newly enrolled in HIV treatment  (i.e. those who registered for antiretroviral therapy) during the reporting period,measure
hiv_reg_new2,Total number of adults and children newly enrolled in HIV treatment  (i.e. those who registered for antiretroviral therapy) during the reporting period,measure
hiv_ret_cmplt,Outcomes for re-treatment HIV-positive TB cases: completed (not used after 2011),measure
hiv_ret_coh,Outcomes for re-treatment HIV-positive TB cases: cohort size (not used after 2011),measure
hiv_ret_cur,Outcomes for re-treatment HIV-positive TB cases: cured (not used after 2011),measure
hiv_ret_def,Outcomes for re-treatment HIV-positive TB cases: defaulted (not used after 2011),measure
hiv_ret_died,Outcomes for re-treatment HIV-positive TB cases: died (not used after 2011),measure
hiv_ret_fail,Outcomes for re-treatment HIV-positive TB cases: failed (not used after 2011),measure
hiv_tbdetect,Total number of adults and children newly enrolled in HIV treatment who are diagnosed as having active TB disease during the reporting period,measure
hiv_tbscr,Number of adults and children enrolled in HIV care who had their TB status assessed and recorded during their last visit,measure
hivtest,TB patients (new and re-treatment) with an HIV test result recorded in the TB register,measure
hivtest_pos,TB patients (new and re-treatment) recorded as HIV-positive,measure
hosp_type_mdr,Type of facility most often used if MDR-TB patients are hospitalized,measure
hospd_dstb_dur,Estimated average duration of stay if patients starting first-line TB treatment are hospitalized (days),measure
hospd_dstb_prct,Estimated percentage of patients starting first-line TB treatment that are hospitalized (%),measure
hospd_mdr_dur,Estimated average duration of stay if patients starting MDR-TB/XDR-TB treatment are hospitalized (days),measure
hospd_mdr_prct,Estimated percentage of patients starting MDR-TB/XDR-TB treatment that are hospitalized (%),measure
ident_pris,Are data on prisoners notified with TB available?,measure
ident_zoonotic,"Were any people diagnosed with TB caused by a subspecies of the M. tuberculosis complex that is usually found in animals, i.e. zoonotic TB (such as M. bovis; M. orygis; M. caprae or M. pinnipedii) in the reporting year?",measure
igra_used,Were Interferon Gamma Release Assays (IGRA) used as tests of TB infection in the public or private sector before starting TB preventive treatment for any population at risk,measure
income_loss,(if social_protn=1) Are there measures to compensate for loss of income?,measure
infection_tests_used,Tests of TB infection used in the public or private sector before starting TB preventive treatment for any population at risk,measure
lab_cul,Number of laboratories providing TB diagnostic services using culture,measure
lab_dst,Number of laboratories providing TB diagnostic services using drug susceptibility testing,measure
lab_dst_eqa,Number of drug susceptibility testing laboratories for which External Quality Assessment (EQA) was carried out,measure
lab_dst_eqa_pass,Number of drug susceptibility testing laboratories which demonstrated acceptable performance,measure
lab_lpa,Number of laboratories providing TB diagnostic services using Line Probe Assay (LPA) rifampicin,measure
lab_lpa_eqa,Number of Line Probe Assay (LPA) rifampicin  laboratories for which External Quality Assessment (EQA) was carried out,measure
lab_lpa_eqa_pass,Number of Line Probe Assay (LPA) rifampicin laboratories which demonstrated acceptable performance,measure
lab_sm,Number of laboratories providing TB diagnostic services using smear microscopy,measure
lab_sm_eqa,Number of smear microscopy laboratories for which External Quality Assessment (EQA) was carried out,measure
lab_sm_eqa_pass,Number of smear microscopy laboratories which demonstrated acceptable performance,measure
lab_sm_led,Number of laboratories providing TB diagnostic services using LED microscopes for smear microscopy,measure
lab_xpert,Number of laboratories providing TB diagnostic services using xpert MTB/RIF,measure
lab_xpert_eqa,Number of laboratories providing TB diagnostic services using xpert MTB/RIF for which External Quality Assessment (EQA) was carried out,measure
lmis,Number of sites which by the end of the reporting year record TB specimen reception and test results in a formal computer-based laboratory information system,measure
lo,Low bound of estimate,measure
lost,Outcomes:  lost to follow up,measure
lpa,Number of sites providing Line Probe Assay services at the end of the reporting year,measure
lpa_eqa_pass,Number of sites providing Line Probe Assay services that demonstrated proficiency by panel testing,measure
lpa_fl,Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for first line drugs (both rifampicin and isoniazid) at the end of the reporting year,measure
lpa_fl_eqa_pass,Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for first line drugs (both rifampicin and isoniazid) that demonstrated proficiency by panel testing in the reporting year,measure
lpa_sl,Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for second line drugs (fluoroquinolones) at the end of the reporting year,measure
lpa_sl_eqa_pass,Number of sites providing TB diagnostic services using Line Probe Assay (LPA) for second line drugs (fluoroquinolones) that demonstrated proficiency by panel testing in the reporting year,measure
m_bovis,(if disagg_zoonotic=1) The number of people diagnosed with M. bovis,measure
m_caprae,(if disagg_zoonotic=1) The number of people diagnosed with M. caprae,measure
m_fq,Number of sites providing TB diagnostic services using molecular tests for detection of fluoroquinolone resistance at the end of the reporting year,measure
m_inh,Number of sites providing TB diagnostic services using molecular tests for detection of isoniazid resistance at the end of the reporting year,measure
m_orygis,(if disagg_zoonotic=1) The number of people diagnosed with M. orygis,measure
m_pinnipedii,(if disagg_zoonotic=1) The number of people diagnosed with M. pinnipedii,measure
m_wrd,Number of sites providing TB diagnostic services using molecular WHO-recommended rapid diagnostics at the end of the reporting year,measure
m_wrd_eqa_pass,Number of sites providing TB diagnostic services using molecular WHO-recommended rapid diagnostics that demonstrated proficiency by panel testing in the reporting year,measure
m_wrd_error_rate_lte_5pct,Number of sites providing molecular WHO-recommended rapid diagnostics testing for TB with annual error rates of 5% or less,measure
m_wrd_etrans,Number of sites using molecular WHO-recommended rapid diagnostics reported in variable m_wrd which by the end of the reporting year transmit results automatically to clinicians and to an information management system,measure
m_wrd_tat_lt_48h,Number of laboratories that achieved a turn-around time within 48 hours for at least 80% of samples received for WHO-recommended rapid diagnostic testing,measure
m_wrd_tests_performed,Total number of diagnostic tests performed using molecular WHO-recommended rapid diagnostics,measure
m_wrd_tests_positive,Number of positive results among the diagnostic tests performed using molecular WHO-recommended rapid diagnostics,measure
mdr_alloral_short_tx,Number of patients started on all oral shorter MDR-TB treatment regimens during the reporting year,measure
mdr_alloral_short_used,Had any patients been started on all oral shorter MDR-TB treatment regimens by the end of the reporting year?,measure
mdr_coh,Outcomes for MDR-TB cases: cohort size,measure
mdr_died,Outcomes for MDR-TB cases: died,measure
mdr_dst_rlt,Drug resistance surveillance: Total number of pulmonary MDR-TB patients with drug susceptibility test results for any fluoroquinolone and any second-line injectable agent,measure
mdr_fail,Outcomes for MDR-TB cases: treatment failed,measure
mdr_lost,Outcomes for MDR-TB cases: lost to follow-up,measure
mdr_new,Drug resistance surveillance: Among new TB patients with available drug susceptibility testing results (variable dst_rlt_new):  number of patients with resistance to isoniazid and rifampicin  (MDR-TB),measure
mdr_ret,Drug resistance surveillance: Among patients previously treated for TB with available drug susceptibility testing results (variable dst_rlt_ret):  number of patients with resistance to isoniazid and rifampicin  (MDR-TB),measure
mdr_shortreg_tx,Number of patients started on shorter MDR-TB treatment regiments during the reporting year,measure
mdr_shortreg_used,Had any patients been started on shorter MDR-TB treatment regimens by the end of the reporting year?,measure
mdr_succ,Outcomes for MDR-TB cases: treatment success (Cured or treatment completed),measure
mdr_tx_adsm,Number of patients who started treatment for MDR-TB/pre-XDR-TB/XDR-TB in the reporting year who are also being actively monitored for adverse events,measure
mdr_tx_adverse_events,Number of patients on MDR-TB treatment who had adverse events registered in the reporting year,measure
mdrxdr_alloral_tx,Number of patients started on all oral longer MDR-TB treatment regimens during the reporting year,measure
mdrxdr_alloral_used,Had any patients been started on all oral longer MDR-TB treatment regimens by the end of reporting year?,measure
mdrxdr_bdq_tx,Number of patients started on Bedaquiline during the reporting year,measure
mdrxdr_bdq_used,Had any TB patients been started on Bedaquiline for the treatment of MDR-TB/pre-XDR-TB/XDR-TB by the end of reporting year?,measure
mdrxdr_bpalm_tx,Number of patients started on the all-oral BPaLM/BPaL regimen for the treatment of MDR/RR-TB or pre-XDR-TB during the reporting year?,measure
mdrxdr_bpalm_used,"Had any patients been started on the all-oral BPaLM/BPaL regimen for the treatment of MDR/RR-TB or, pre-XDR-TB  by the end of reporting year?",measure
mdrxdr_dlm_tx,Number of patients started on Delamanid during the reporting year,measure
mdrxdr_dlm_used,"Had any TB patients been started on Delamanid for the treatment of MDR-/XDR-TB by the end of reporting as part of expanded access, compassionate use or under normal programmatic use, whether in the public or private sector?",measure
measure,The measure of TB burden being estimated,measure
min_agg_collab,How is the ministry of agriculture or its equivalent  engaged in the national TB response?,measure
min_def_collab,How is the ministry of defence or its equivalent  engaged in the national TB response?,measure
min_dev_collab,How is the ministry of social development or its equivalent  engaged in the national TB response?,measure
min_edu_collab,How is the ministry of education or its equivalent  engaged in the national TB response?,measure
min_fin_collab,How is the ministry of finance or its equivalent  engaged in the national TB response?,measure
min_jus_collab,How is the ministry of justice or its equivalent  engaged in the national TB response?,measure
min_lab_collab,How is the ministry of labour or its equivalent  engaged in the national TB response?,measure
min_tra_collab,How is the ministry of transport or its equivalent  engaged in the national TB response?,measure
miners,(if miners_screen_data_available=1) Number of miners exposed to silica dust,measure
miners_screen,(if miners_screen_data_available=1) Number of miners who were screened for TB,measure
miners_screen_data_available,Are data available on the number of miners exposed to silica dust screened for TB?,measure
ms_review,Is there a national multi-sectoral and multi-stakeholder accountability and review mechanism under high-level leadership to monitor and review progress towards ending TB?,measure
ms_review_civil_soc,Do representatives of civil society and affected communities participate in the multi-sectoral accountability and review mechanism?,measure
neval,Outcomes:  not evaluated,measure
new_clindx,"New pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician or another medical practitioner who has decided to give the patient a full course of TB treatment).  It also includes pulmonary clinically diagnosed cases with unknown previous TB treatment history.",measure
new_ep,New extrapulmonary cases (bacteriologically confirmed or clinically diagnosed). As of 2013 this also includes extrapulmonary cases with unknown previous TB treatment history.,measure
new_ep_f014,New extrapulmonary cases: females aged 0-14 years (not used after 2012),measure
new_ep_f04,New extrapulmonary cases: females aged 0-4 years (not used after 2012),measure
new_ep_f1524,New extrapulmonary cases: females aged 15-24 years (not used after 2012),measure
new_ep_f15plus,New extrapulmonary cases: females aged 15 years and over (not used after 2012),measure
new_ep_f2534,New extrapulmonary cases: females aged 25-34 years (not used after 2012),measure
new_ep_f3544,New extrapulmonary cases: females aged 35-44 years (not used after 2012),measure
new_ep_f4554,New extrapulmonary cases: females aged 45-54 years (not used after 2012),measure
new_ep_f514,New extrapulmonary cases: females aged 5-14 years (not used after 2012),measure
new_ep_f5564,New extrapulmonary cases: females aged 55-64 years (not used after 2012),measure
new_ep_f65,New extrapulmonary cases: females aged 65 years and over (not used after 2012),measure
new_ep_fu,New extrapulmonary cases: females age unknown (not used after 2012),measure
new_ep_m014,New extrapulmonary cases: males aged 0-14 years (not used after 2012),measure
new_ep_m04,New extrapulmonary cases: males aged 0-4 years (not used after 2012),measure
new_ep_m1524,New extrapulmonary cases: males aged 15-24 years (not used after 2012),measure
new_ep_m15plus,New extrapulmonary cases: males aged 15 years and over (not used after 2012),measure
new_ep_m2534,New extrapulmonary cases: males aged 25-34 years (not used after 2012),measure
new_ep_m3544,New extrapulmonary cases: males aged 35-44 years (not used after 2012),measure
new_ep_m4554,New extrapulmonary cases: males aged 45-54 years (not used after 2012),measure
new_ep_m514,New extrapulmonary cases: males aged 5-14 years (not used after 2012),measure
new_ep_m5564,New extrapulmonary cases: males aged 55-64 years (not used after 2012),measure
new_ep_m65,New extrapulmonary cases: males aged 65 years and over (not used after 2012),measure
new_ep_mu,New extrapulmonary cases: males age unknown (not used after 2012),measure
new_ep_sexunk014,"New extrapulmonary cases: sex unknown, aged 0-14 years (not used after 2012)",measure
new_ep_sexunk04,"New extrapulmonary cases: sex unknown, aged 0-4 years (not used after 2012)",measure
new_ep_sexunk15plus,"New extrapulmonary cases: sex unknown, aged 15 years and over (not used after 2012)",measure
new_ep_sexunk514,"New extrapulmonary cases: sex unknown, aged 5-14 years (not used after 2012)",measure
new_ep_sexunkageunk,"New extrapulmonary cases: sex unknown, age unknown (not used after 2012)",measure
new_labconf,New pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics such as Xpert MTB/RIF). As of 2013 this also includes pulmonary bacteriologically confirmed cases with unknown previous TB treatment history.,measure
new_oth,Other new cases (not used after 2012),measure
new_sn,New pulmonary smear-negative cases (not used after 2012),measure
new_sn_f014,New pulmonary smear negative/smear unknown/smear not done cases: females aged 0-14 years (not used after 2012),measure
new_sn_f04,New pulmonary smear negative/smear unknown/smear not done cases: females aged 0-4 years (not used after 2012),measure
new_sn_f1524,New pulmonary smear negative/smear unknown/smear not done cases: females aged 15-24 years (not used after 2012),measure
new_sn_f15plus,New pulmonary smear negative/smear unknown/smear not done cases: females aged 15 years and over (not used after 2012),measure
new_sn_f2534,New pulmonary smear negative/smear unknown/smear not done cases: females aged 25-34 years (not used after 2012),measure
new_sn_f3544,New pulmonary smear negative/smear unknown/smear not done cases: females aged 35-44 years (not used after 2012),measure
new_sn_f4554,New pulmonary smear negative/smear unknown/smear not done cases: females aged 45-54 years (not used after 2012),measure
new_sn_f514,New pulmonary smear negative/smear unknown/smear not done cases: females aged 5-14 years (not used after 2012),measure
new_sn_f5564,New pulmonary smear negative/smear unknown/smear not done cases: females aged 55-64 years (not used after 2012),measure
new_sn_f65,New pulmonary smear negative/smear unknown/smear not done cases: females aged 65 years and over (not used after 2012),measure
new_sn_fu,New pulmonary smear negative/smear unknown/smear not done cases: females age unknown (not used after 2012),measure
new_sn_m014,New pulmonary smear negative/smear unknown/smear not done cases: males aged 0-14 years (not used after 2012),measure
new_sn_m04,New pulmonary smear negative/smear unknown/smear not done cases: males aged 0-4 years (not used after 2012),measure
new_sn_m1524,New pulmonary smear negative/smear unknown/smear not done cases: males aged 15-24 years (not used after 2012),measure
new_sn_m15plus,New pulmonary smear negative/smear unknown/smear not done cases: males aged 15 years and above (not used after 2012),measure
new_sn_m2534,New pulmonary smear negative/smear unknown/smear not done cases: males aged 25-34 years (not used after 2012),measure
new_sn_m3544,New pulmonary smear negative/smear unknown/smear not done cases: males aged 35-44 years (not used after 2012),measure
new_sn_m4554,New pulmonary smear negative/smear unknown/smear not done cases: males aged 45-54 years (not used after 2012),measure
new_sn_m514,New pulmonary smear negative/smear unknown/smear not done cases: males aged 5-14 years (not used after 2012),measure
new_sn_m5564,New pulmonary smear negative/smear unknown/smear not done cases: males aged 55-64 years (not used after 2012),measure
new_sn_m65,New pulmonary smear negative/smear unknown/smear not done cases: males aged 65 years and over (not used after 2012),measure
new_sn_mu,New pulmonary smear negative/smear unknown/smear not done cases: males age unknown (not used after 2012),measure
new_sn_sexunk014,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 0-14 years (not used after 2012)",measure
new_sn_sexunk04,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 0-4 years (not used after 2012)",measure
new_sn_sexunk15plus,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 15 years and over (not used after 2012)",measure
new_sn_sexunk514,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, aged 5-14 years (not used after 2012)",measure
new_sn_sexunkageunk,"New pulmonary smear negative/smear unknown/smear not done cases: sex unknown, age unknown (not used after 2012)",measure
new_snep_cmplt,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: completed (not used after 2011),measure
new_snep_coh,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: cohort size (not used after 2011),measure
new_snep_def,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: defauled (not used after 2011),measure
new_snep_died,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: died (not used after 2011),measure
new_snep_fail,Outcomes for new pulmonary smear-negative/extrapulmonary/smear unknown/smear not done cases: failed (not used after 2011),measure
new_sp,New pulmonary smear-positive cases (not used after 2012),measure
new_sp_cmplt,Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: completed (not used after 2011),measure
new_sp_coh,Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: cohort size (not used after 2011),measure
new_sp_cur,Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: cured (not used after 2011),measure
new_sp_def,Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: defaulted (not used after 2011),measure
new_sp_died,Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: died (not used after 2011),measure
new_sp_f014,New pulmonary smear positive cases: females aged 0-14 years (not used after 2012),measure
new_sp_f04,New pulmonary smear positive cases: females aged 0-4 years (not used after 2012),measure
new_sp_f1524,New pulmonary smear positive cases: females aged 15-24 years (not used after 2012),measure
new_sp_f2534,New pulmonary smear positive cases: females aged 25-34 years (not used after 2012),measure
new_sp_f3544,New pulmonary smear positive cases: females aged 35-44 years (not used after 2012),measure
new_sp_f4554,New pulmonary smear positive cases: females aged 45-54 years (not used after 2012),measure
new_sp_f514,New pulmonary smear positive cases: females aged 5-14 years (not used after 2012),measure
new_sp_f5564,New pulmonary smear positive cases: females aged 55-64 years (not used after 2012),measure
new_sp_f65,New pulmonary smear positive cases: females aged 65 and over (not used after 2012),measure
new_sp_fail,Outcomes for new pulmonary smear-positive (and/or culture-positive) cases: failed (not used after 2011),measure
new_sp_fu,New pulmonary smear positive cases: females age unknown (not used after 2012),measure
new_sp_m014,New pulmonary smear positive cases: males aged 0-14 years (not used after 2012),measure
new_sp_m04,New pulmonary smear positive cases: males aged 0-4 years (not used after 2012),measure
new_sp_m1524,New pulmonary smear positive cases: males aged 15-24 years (not used after 2012),measure
new_sp_m2534,New pulmonary smear positive cases: males aged 25-34 years (not used after 2012),measure
new_sp_m3544,New pulmonary smear positive cases: males aged 35-44 years (not used after 2012),measure
new_sp_m4554,New pulmonary smear positive cases: males aged 45-54 years (not used after 2012),measure
new_sp_m514,New pulmonary smear positive cases: males aged 5-14 years (not used after 2012),measure
new_sp_m5564,New pulmonary smear positive cases: males aged 55-64 years (not used after 2012),measure
new_sp_m65,New pulmonary smear positive cases: males aged 65 years and over (not used after 2012),measure
new_sp_mu,New pulmonary smear positive cases: males age unknown (not used after 2012),measure
new_su,New pulmonary smear unknown/not done cases,measure
newinc_con,(If screen_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases,measure
newinc_con04_prevtx,(If prevtx_data_available=60) Number of children aged under 5 started on TB preventive treatment who are household contacts of bacteriologically-confirmed new and relapse TB cases notified,measure
newinc_con5plus_prevtx,"(If prevtx_5plus_data_available=60 and year=2017) Number of children aged 5 years and above, adolescents and adults started on TB preventive therapy who are household contacts of bacteriologically-confirmed new and relapse TB cases notified",measure
newinc_con_prevtx,(If prevtx_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases notified in the reporting year who were started on TB preventive treatment,measure
newinc_con_prevtx_cmplt,"Among household contacts reported in newinc_con_prevtx, number who completed the course of TB preventive treatment",measure
newinc_con_screen,(If screen_data_available=60) Number of household contacts of bacteriologically-confirmed pulmonary new and relapse TB cases who were evaluated for active TB and latent TB,measure
newinc_con_tb,(If screen_data_available=60) Number of household contacts of bacteriologically confirmed pulmonary new and relapse TB cases who were diagnosed with TB disease,measure
newinc_ep_rdx,(if rdx_data_available=62) Number of new and relapse extrapulmonary cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result),measure
newinc_from_screen,"(if tb_from_screen_available=1) The number of new and relapse TB cases who were reported through TB screening efforts (eg, screening in contacts, people living with HIV, prisons, mining communities, facility-based screening of people with diabetes and other groups, other active case-finding)",measure
newinc_pulm_clindx_rdx,(if rdx_data_available=62) Number of new and relapse pulmonary clinically diagnosed cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result),measure
newinc_pulm_labconf_rdx,(if rdx_data_available=62) Number of new and relapse pulmonary bacteriologically confirmed cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result),measure
newinc_rdx,(if rdx_data_available=60) Number of new and relapse cases notified and tested using a WHO-recommended rapid diagnostic (for example Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result),measure
newrel_art,"HIV-positive new and relapse (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients started or continued on antiretroviral therapy",measure
newrel_art_014,Number of HIV-positive new and relapse TB patients aged 0-14 years who started or continued on antiretroviral therapy,measure
newrel_coh,Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): cohort size,measure
newrel_died,Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): died,measure
newrel_ep_labconf,"(if ep_spec_available=1) Among the new and relapse extrapulmonary TB cases reported in new_ep and ret_rel_ep, the number of cases that were bacteriologically confirmed, i.e. by culture or molecular technologies",measure
newrel_ep_mbovis,"(if ep_spec_available=1) Among extrapulmonary TB cases with test results for speciation reported in newrel_ep_spec, number of cases identified as having Mycobacterium bovis",measure
newrel_ep_spec,"(if ep_spec_available=1) Among bacteriologically confirmed extrapulmonary TB cases reported in newrel_ep_labconf, number of cases with test results for the speciation of the Mycobacterium tuberculosis complex",measure
newrel_f014,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 0-14 years,measure
newrel_f04,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 0-4 years,measure
newrel_f1014,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 10-14 years,measure
newrel_f1519,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15-19 years,measure
newrel_f1524,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15-24 years,measure
newrel_f15plus,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 15 years and over,measure
newrel_f2024,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 20-24 years,measure
newrel_f2534,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 25-34 years,measure
newrel_f3544,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 35-44 years,measure
newrel_f4554,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 45-54 years,measure
newrel_f514,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 5-14 years,measure
newrel_f5564,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 55-64 years,measure
newrel_f59,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 5-9 years,measure
newrel_f65,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females aged 65 years and over,measure
newrel_fail,Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): treatment failed,measure
newrel_fu,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): females age unknown,measure
newrel_hivpos,"Number of new and relapse  (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients recorded as HIV-positive",measure
newrel_hivpos_014,Number of new and relapse TB patients aged 0-14 years recorded as HIV-positive,measure
newrel_hivtest,"Number of new and relapse (or all, if newrel_tbhiv_flg = 0 and year > 2015) TB patients tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis",measure
newrel_hivtest_014,Number of new and relapse TB patients aged 0-14 years tested for HIV at the time of TB diagnosis or with known HIV status at the time of TB diagnosis,measure
newrel_lost,Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): lost to follow-up,measure
newrel_m014,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 0-14 years,measure
newrel_m04,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 0-4 years,measure
newrel_m1014,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 10-14 years,measure
newrel_m1519,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15-19 years,measure
newrel_m1524,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15-24 years,measure
newrel_m15plus,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 15 years and over,measure
newrel_m2024,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 20-24 years,measure
newrel_m2534,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 25-34 years,measure
newrel_m3544,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 35-44 years,measure
newrel_m4554,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 45-54 years,measure
newrel_m514,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 5-14 years,measure
newrel_m5564,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 55-64 years,measure
newrel_m59,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 5-9 years,measure
newrel_m65,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males aged 65 years and over,measure
newrel_mu,New and relapse cases (but only new cases if rel_in_agesex_flg = 0): males age unknown,measure
newrel_prisoners,(if ident_pris=1) Number of new and relapse TB cases registered in prisons,measure
newrel_pulm_mbovis,"(if pulm_spec_available=1) Among pulmonary cases with test results for speciation reported in newrel_pulm_spec, number of cases identified as having Mycobacterium bovis",measure
newrel_pulm_spec,"(if pulm_spec_available=1) Among bacteriologically confirmed new and relapse pulmonary TB cases, number of cases with test results for the speciation of the Mycobacterium tuberculosis complex",measure
newrel_sexunk014,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 0-14 years",measure
newrel_sexunk04,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 0-4 years",measure
newrel_sexunk15plus,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 15 years and over",measure
newrel_sexunk514,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, aged 5-14 years",measure
newrel_sexunkageunk,"New and relapse cases (but only new cases if rel_in_agesex_flg = 0): sex unknown, age unknown",measure
newrel_succ,Outcomes for all new and relapse cases (but only new cases if rel_with_new_flg = 0): treatment success (cured or treatment completed),measure
newrel_tbhiv_flg,"Are data on HIV testing, HIV positivity and provision of antiretroviral therapy (ART) restricted to new and relapse TB cases only?",measure
newret_oth,Other cases not included in new and re-treatment case numbers,measure
notif_foreign,New and re-treatment TB cases among foreign-born individuals,measure
notified_ref,Total number of new and relapse TB cases notified in the Basic Management Units with data on referrals by community health workers,measure
notified_ref_community,Total number of new and relapse TB cases referred by community health workers / community volunteers in the Basic Management Units with data on referrals by community health workers,measure
nrl,Was there a national reference laboratory or laboratories (NRL)?,measure
nrl_iso15189,Has the national reference laboratory (or national reference laboratories) achieved national or international accreditation according to the ISO 15189 standard?,measure
nrl_qms,Has a formal quality management system towards achieving laboratory accreditation been implemented at the National Reference Laboratory?,measure
nrl_srl_link,Has a formal link been established between the National Reference Laboratory and a partner Supranational Reference Laboratory?,measure
nrr,Number of TB cases with no evidence of rifampicin resistance (either rifampicin susceptible or tests for susceptibility to rifampicin not done),measure
nrr_014,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are aged 0-14 years",measure
nrr_15plus,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are aged 15 years and over",measure
nrr_2hrze2hr_tx,(if nrr_2hrze2hr_used=1) Number of patients started on the 4-month 2HRZ(E)/ 2HR regimen,measure
nrr_2hrze2hr_used,Had any TB patients been started on the 4-month 2HRZ(E)/ 2HR regimen for the treatment of non-severe rifampicin-susceptible TB by the end of reporting year?,measure
nrr_ageunk,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and whose age is unknown",measure
nrr_hivneg,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are HIV-negative",measure
nrr_hivpos,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and who are HIV-positive",measure
nrr_hivunk,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number susceptible to rifampicin and whose HIV status is unknown",measure
nrr_hpmz_tx,Number of patients started on the 4-month HPMZ regimen for the treatment of rifampicin-susceptible TB during the reporting year?,measure
nrr_hpmz_used,Had any patients been started on the 4-month HPMZ regimen for the treatment of rifampicin-susceptible TB by the end of reporting year?,measure
nrr_tx,Number of TB cases with no evidence of rifampicin resistance (either rifampicin susceptible or tests for susceptibility to rifampicin not done) started on a regimen to treat rifampicin-susceptible TB,measure
people_cash_trans,(if cash_trans=1) The number of people started on TB treatment who were provided with conditional and/or unconditional cash-transfers,measure
people_tx_enablers,(if enable_tx_adherence=1) The number of people started on TB treatment who were provided with enablers to adhere to TB treatment,measure
phcf,Total number of primary health-care facilities,measure
phcf_wrd,Number of primary health-care facilities with access to WHO-recommended rapid diagnostic tests (either on site or through a sample referral system),measure
plhiv_all,(if plhiv_all_screen_data_available=1) Total number of people living with HIV,measure
plhiv_all_screen,(if plhiv_all_screen_data_available=1) Number of people living with HIV who were screened for TB,measure
plhiv_all_screen_data_available,Are data available on the number of people living with HIV screened for TB?,measure
plhiv_new,(if plhiv_new_screen_data_available=1) Number of people newly diagnosed with HIV,measure
plhiv_new_screen,(if plhiv_new_screen_data_available=1) Number of people newly diagnosed with HIV who were screened for TB,measure
plhiv_new_screen_data_available,Are data available on the number of people newly diagnosed with HIV and screened for TB?,measure
presumptive,Number of people identified with presumptive TB,measure
presumptive_wrd,Number of people identified with presumptive TB who were tested with a WHO-recommended rapid diagnostic test,measure
prevtx_5plus_data_available,"(for year=2017 only) Are data available on the number of children aged 5 years and above, adolescents and adults who are household contacts of TB cases and started on TB preventive therapy?",measure
prevtx_data_available,Are data available on the number of household contacts of TB cases started on TB preventive treatment?,measure
prevtx_short_data_available,Are data available on the number of patients treated using shorter TB preventive treatment regimens containing rifampicin or rifapentine?,measure
prevtx_short_rifamycin,(if prevtx_short_data_available=1) Total number of individuals started on shorter TB preventive treatment regimens containing rifampicin or rifapentine in the reporting year,measure
prisoners,(if prisoners_screen_data_available=1) Total number of prisoners,measure
prisoners_screen,(if prisoners_screen_data_available=1) Number of prisoners in who were screened for TB,measure
prisoners_screen_data_available,Are data available on the number of prisoners screened for TB?,measure
priv_new_dx,Number of new cases of TB diagnosed according to National Treatment Programme (NTP)  guidelines by private providers,measure
protect_association,Is freedom of association for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. no compulsory isolation because of a TB diagnosis),measure
protect_employment,Is employment for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. not being dismissed because of a TB diagnosis),measure
protect_housing,Is housing for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. not being evicted from housing facilities because of a TB diagnosis),measure
protect_movement,Is freedom of movement for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. no restriction to access any congregate setting or transit through any geographical area because of a TB diagnosis),measure
protect_parenting,Are parental rights for people with TB protected from stigma and discrimination through national laws and regulations? (e.g. not having parental rights over children affected in any way as a result of TB diagnosis of a parent),measure
ptsurvey_newinc,(If prevtx_data_available=61) Number of bacteriologically-confirmed TB new and relapse cases notified in the reporting year whose medical records or treatment cards were included in a survey,measure
ptsurvey_newinc_5plus,(If prevtx_5plus_data_available=61 and year=2017) Number of bacteriologically-confirmed TB new and relapse cases notified in the reporting year whose medical records or treatment cards were included in a survey,measure
ptsurvey_newinc_con04_prevtx,(If prevtx_data_available=61) Number of children aged under 5 started on TB preventive treatment who are household contacts of the TB cases in ptsurvey_newinc,measure
ptsurvey_newinc_con5plus_prevtx,"(If prevtx_5plus_data_available=61 and year=2017) Number of children aged 5 years and above, adolescents and adults started on TB preventive therapy who are household contacts of the TB cases in ptsurvey_newinc_5plus",measure
ptsurvey_newinc_con_prevtx,(If prevtx_data_available=61) Number of household contacts of the TB cases surveyed in ptsurvey_newinc who were started on TB preventive treatment.,measure
pub_new_dx,Number of new cases of TB diagnosed according to National Treatment Programme (NTP)  guidelines by non-NTP public providers,measure
pulm_labconf_new,Number of new bacteriologically confirmed pulmonary TB cases,measure
pulm_labconf_ret,Number of previously treated bacteriologically confirmed pulmonary TB cases,measure
pulm_labconf_unk,Number of bacteriologically confirmed pulmonary TB cases with unknown TB treatment history,measure
pulm_spec_available,Are data available on the number of bacteriologically confirmed pulmonary TB cases with test results for the speciation of the Mycobacterium tuberculosis complex in the reporting year?,measure
qms,"Is a formal quality management system towards achieving accreditation being implemented in all laboratories conducting culture, LPA and/or DST?",measure
qms_pending,Number of sites that by the end of the reporting year are not accredited and that are in the process of establishing a formal quality management system towards achieving accreditation,measure
r_rlt_new,Number of new bacteriologically confirmed pulmonary TB patients with test results for rifampicin,measure
r_rlt_rel,Number of bacteriologically confirmed pulmonary relapse TB patients with test results for rifampicin,measure
r_rlt_ret,Number of previously treated bacteriologically confirmed pulmonary TB patients with test results for rifampicin,measure
rcvd_fld,Funding received for drugs to treat drug-susceptible TB (US Dollars),measure
rcvd_lab,"Funding received for laboratory infrastructure, equipment and supplies (US Dollars)",measure
rcvd_mdrmgt,Funding received for programme costs to treat drug-resistant TB (US Dollars),measure
rcvd_orsrvy,Funding received for operational research and surveys (US Dollars),measure
rcvd_oth,Funding received for all other budget line items (US Dollars),measure
rcvd_patsup,Funding received for patient support (US Dollars),measure
rcvd_prog,Funding received for programme costs to treat drug-susceptible TB (US Dollars),measure
rcvd_sld,Funding received for drugs to treat drug-resistant TB (US Dollars),measure
rcvd_staff,Funding received for National TB Programme staff (central unit staff and subnational TB staff)  (US Dollars),measure
rcvd_tbhiv,Funding received for collaborative TB/HIV activities (US Dollars),measure
rcvd_tot,Total funding received for all budget line items (US Dollars),measure
rcvd_tot_domestic,"Funding received from domestic sources, including loans (US Dollars)",measure
rcvd_tot_gf,"Funding received from the Global Fund to Fight AIDS, Tuberculosis and Malaria (US Dollars)",measure
rcvd_tot_grnt,Funding received from other sources (US Dollars),measure
rcvd_tot_usaid,Funding received from USAID (US Dollars),measure
rcvd_tpt,Funding received for drugs for TB preventive treatment (US Dollars),measure
rdst_new,"Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: new cases",measure
rdst_ret,"Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: previously treated cases",measure
rdst_unk,"Number of TB cases (pulmonary or extrapulmonary) tested for susceptibility to rifampicin using phenotypic DST or WHO-recommended rapid molecular diagnostics (e.g. Xpert MTB/RIF), before or after starting treatment: cases with unknown previous TB treatment history",measure
rdx_data_available,Are data available on the number of new and relapse cases tested using a WHO-recommended rapid diagnostic during the reporting year?,measure
rdxsurvey_newinc,(if rdx_data_available=61) Number of new and relapse cases whose medical records or treatment cards were included in the survey,measure
rdxsurvey_newinc_rdx,(if rdx_data_available=61) Among the cases reported in rdxsurvey_newinc the number tested using a WHO-recommended rapid diagnostic (such as Xpert MTB/RIF) at the time of TB diagnosis (regardless of test result),measure
rel_in_agesex_flg,Are all relapse cases included with new cases in the disaggregations by age and sex?,measure
rel_with_new_flg,Are outcomes of relapse cases included in the newrel outcome variables?,measure
rep_meth,Method of confirmation used to report treatment outcomes of pulmonary cases  (not used after 2011),measure
report_coverage,Indicates whether or not provisional data include data from all reporting units in the country,measure
report_frequency,Frequency at which provisional data are reported to WHO,measure
ret_cmplt,Outcomes for re-treatment cases: completed  (not used after 2011),measure
ret_coh,Outcomes for re-treatment cases: cohort size (not used after 2011),measure
ret_cur,Outcomes for re-treatment cases: cured (not used after 2011),measure
ret_def,Outcomes for re-treatment cases: defaulted (not used after 2011),measure
ret_died,Outcomes for re-treatment cases: died (not used after 2011),measure
ret_fail,Outcomes for re-treatment cases: failed (not used after 2011),measure
ret_nrel,"Previously treated patients, excluding relapse cases (pulmonary or extrapulmonary, bacteriologically confirmed or clinically diagnosed)",measure
ret_nrel_coh,Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): cohort size,measure
ret_nrel_died,Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): died,measure
ret_nrel_fail,Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): treatment failed,measure
ret_nrel_lost,Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): lost to follow-up,measure
ret_nrel_succ,Outcomes for previously treated patients (excluding relapse cases if rel_with_new_flg = 1): treatment success (cured or treatment completed),measure
ret_oth,Other re-treatment cases,measure
ret_rel,Relapse cases,measure
ret_rel_clindx,"Relapse pulmonary clinically diagnosed TB cases (not bacteriologically confirmed as positive for TB, but diagnosed with active TB by a clinician or another medical practitioner who has decided to give the patient a full course of TB treatment).",measure
ret_rel_ep,Relapse extrapulmonary cases (bacteriologically confirmed or clinically diagnosed),measure
ret_rel_labconf,Relapse  pulmonary bacteriologically confirmed TB cases (smear positive or culture positive or positive by WHO-recommended rapid diagnostics such as Xpert MTB/RIF).,measure
ret_tad,Treatment after default cases,measure
ret_taf,Treatment after failure cases,measure
rev_newinc,(If screen_data_available=61) Number of bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review,measure
rev_newinc_con,(If screen_data_available=61) Number of household contacts identified from the bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review,measure
rev_newinc_con_screen,(If screen_data_available=61) Number of household contacts who were evaluated for active TB and latent TB identified from the bacteriologically-confirmed pulmonary new and relapse TB cases whose medical records or treatment cards were included in the review,measure
rev_newinc_con_tb,(If screen_data_available=61) Number of household contacts of bacteriologically confirmed pulmonary new and relapse TB cases who were diagnosed with TB disease and whose medical records or treatment cards were included in the review,measure
rr_014,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are aged 0-14 years",measure
rr_15plus,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are aged 15 years and over",measure
rr_ageunk,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and whose age is unknown",measure
rr_dr_2li,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to second-line injectable agents,measure
rr_dr_fq,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to fluoroquinolones,measure
rr_dr_fq_2li,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to both fluoroquinolones and second-line injectable agents,measure
rr_ds_fq2li,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and susceptible to both fluoroquinolones and second-line injectable agents,measure
rr_dst_rlt,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and with test results for any fluoroquinolone and any second-line injectable agent,measure
rr_dst_rlt_fq,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and with test results for any fluoroquinolone,measure
rr_fqr,Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and resistance to fluoroquinolones,measure
rr_fqr_bdqr_lzdr,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones, bedaquiline and linezolid.",measure
rr_fqr_bdqr_lzds,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and bedaquiline but susceptible to linezolid.",measure
rr_fqr_bdqr_lzdu,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and bedaquiline but unknown resistance to linezolid.",measure
rr_fqr_bdqs_lzdr,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and linezolid, but susceptible to bedaquiline.",measure
rr_fqr_bdqs_lzds,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones but susceptible to bedaquiline and linezolid.",measure
rr_fqr_bdqs_lzdu,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and fluoroquinolones, but susceptible to bedaquiline and with unknown resistance to linezolid.",measure
rr_fqr_bdqu_lzdr,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones and linezolid, but unknown resistance to bedaquiline.",measure
rr_fqr_bdqu_lzds,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin, fluoroquinolones but susceptible to linezolid and unknown resistance to bedaquiline.",measure
rr_fqr_bdqu_lzdu,"Number of new or previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin and fluoroquinolones, but with unknown resistance to bedaquiline and linezolid.",measure
rr_hivneg,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are HIV-negative",measure
rr_hivpos,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and who are HIV-positive",measure
rr_hivunk,"Among patients with results for rifampicin testing in r_rlt_new and r_rlt_ret, number resistant to rifampicin and whose HIV status is unknown",measure
rr_new,Number of new bacteriologically confirmed pulmonary TB patients with resistance to rifampicin (RR-TB),measure
rr_nfqr_014_tx,The number of children aged 0-14 years among patients who started treatment for MDR/RR-TB,measure
rr_rel,Number of bacteriologically confirmed pulmonary relapse TB patients  with resistance to rifampicin (RR-TB),measure
rr_ret,Number of previously treated bacteriologically confirmed pulmonary TB patients with resistance to rifampicin (RR-TB),measure
rr_sldst,Number of laboratory-confirmed RR-TB or MDR-TB cases tested for susceptibility to second-line drugs (fluoroquinolones and second-line injectable agents),measure
rrmdr_014_tx,The number of children aged 0-14 years among patients who started treatment for MDR-TB (regardless of whether rifampicin resistance was confirmed),measure
rxsupport_community_coh,Total number of patients who started TB treatment and who received any form of treatment adherence support from community health workers / community volunteers in the Basic Management Units with data on community treatment adherence support,measure
rxsupport_community_succ,Total number of patients who were cured or who completed treatment among the cases who started TB treatment and who received any form of treatment adherence support from community health workers / community volunteers in the Basic Management Units with data on community treatment adherence support,measure
screen_data_available,Are data available on the number of household contacts of TB cases who were evaluated for TB?,measure
sldst,Number of sites providing phenotypic drug susceptibility testing for first-line drugs and second-line drugs at the end of the reporting year,measure
sldst_avail_incntry,Was second-line drug susceptibility testing available within the country for TB National Treatment Programme patients?,measure
sldst_avail_outcntry,Was second-line drug susceptibility testing available outside the country for TB National Treatment Programme patients?,measure
sldst_eqa_pass,Number of sites providing phenotypic drug susceptibility testing for first-line drugs and second-line drugs that demonstrated proficiency by panel testing,measure
sllpa,"Number of sites providing Line Probe Assay (LPA) services for rifampicin, isoniazid, fluoroquinolones, second-line injectables",measure
sllpa_eqa_pass,"Number of sites providing Line Probe Assay (LPA) services for rifampicin, isoniazid, fluoroquinolones, second-line injectables that demonstrated proficiency by panel testing",measure
smear,Number of sites providing TB diagnostic services using smear microscopy (including fluorescent) at the end of the reporting year,measure
smear_eqa,Number of sites providing TB diagnostic services using smear microscopy covered by a comprehensive EQA system,measure
smear_eqa_pass,Number of sites providing TB diagnostic services using smear microscopy (including fluorescent) that demonstrated proficiency by panel testing in the reporting year,measure
social_protn,Is there a national policy to specifically provide social protection services to TB-affected individuals?,measure
succ,Outcomes: treatment success (Cured or treatment completed),measure
tb_from_screen_available,"Are data available on the number of TB cases who were reported through TB screening efforts (eg, screening in contacts, people living with HIV, prisons, mining communities, facility-based screening of people with diabetes and other groups, other active case-finding)?",measure
tbhiv_014_flg,Are data on TB/HIV indicators available for new and relapse TB patients that are children aged 0-14 years?,measure
tbhiv_coh,"Outcomes for HIV-positive TB cases, all types: cohort size",measure
tbhiv_died,"Outcomes for HIV-positive TB cases, all types: died",measure
tbhiv_fail,"Outcomes for HIV-positive TB cases, all types: treatment failed",measure
tbhiv_lost,"Outcomes for HIV-positive TB cases, all types: lost to follow-up",measure
tbhiv_sentin_cil,Lower limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using sentinel sites,measure
tbhiv_sentin_ciu,Upper limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using sentinel sites,measure
tbhiv_sentin_prev,Prevalence (%) of HIV in TB patients estimated using sentinel sites,measure
tbhiv_sentin_yr,Year in which prevalence of HIV in TB patients was estimated using sentinel sites,measure
tbhiv_succ,"Outcomes for HIV-positive TB cases, all types: treatment success (cured or treatment completed)",measure
tbhiv_surv_cil,Lower limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using nationwide representative surveys,measure
tbhiv_surv_ciu,Upper limit (95% confidence interval) of prevalence (%) of HIV in TB patients estimated using nationwide representative surveys,measure
tbhiv_surv_prev,"Prevalence (%) of HIV in TB patients estimated using nationwide representative
surveys",measure
tbhiv_surv_yr,Year in which prevalence of HIV in TB patients was estimated using nationwide representative surveys,measure
tbst_used,Were antigen-based skin tests (TBST) used as tests of TB infection in the public or private sector before starting TB preventive treatment for any population at risk,measure
tpt_1hp,(If tpt_short_regimens_used=1) Was the 1 month daily rifapentine and isoniazid (1HP) TB preventive treatment regimen used at least once?,measure
tpt_3hp,(If tpt_short_regimens_used=1) Was the 3 month weekly rifapentine and isoniazid (3HP) TB preventive treatment regimen used at least once?,measure
tpt_3hr,(If tpt_short_regimens_used=1) Was the 3 month daily rifampicin and isoniazid (3HR) TB preventive treatment regimen used at least once?,measure
tpt_4r,(If tpt_short_regimens_used=1) Was the 4 month daily rifampicin (4R) TB preventive treatment regimen used at least once?,measure
tpt_6lfx,Was TB preventive treatment with 6 month daily levofloxacin (6Lfx) used at least once in contacts exposed to MDR/RR-TB?,measure
tpt_short_regimens_used,Were any shorter TB preventive treatment regimes containing rifampicin or rifapentine used at least once?,measure
tsr,Treatment success rate as a percentage,measure
tst_used,Were tuberculin skin tests (TST) used as tests of TB infection in the public or private sector before starting TB preventive treatment for any population at risk,measure
tx_dstb,Number of patients expected to start drug-susceptible TB treatment,measure
tx_mdr,Number of patients expected to start MDR-TB treatment,measure
tx_tpt,Number of patients expected to start TB preventive treatment,measure
tx_xdr,Number of patients expected to start pre-XDR/XDR-TB treatment,measure
unconf_mdr_tx,Number of MDR-TB (not laboratory-confirmed) patients who started treatment for MDR-TB,measure
unconf_rr_nfqr_tx,Number of patients (not laboratory-confirmed as having resistance to rifampicin and with no known resistance to any fluoroquinolones) who started treatment for MDR-TB. (This does not include patients treated for pre-XDR-TB or XDR-TB).,measure
unconf_rrmdr_tx,Number of patients (not laboratory-confirmed as having rifampicin-resistant (RR-TB) or multidrg-resistant TB (MDR-TB)) who started treatment for MDR-TB,measure
unit,The unit of measurement,measure
used_2021_defs_flg,Are outcomes for both drug-susceptible and drug-resistant TB reported in line with the revised definitions published by WHO in April 2021 at https://www.who.int/publications/i/item/9789240022195?,measure
wrd_test_capacity,Number of WHO-recommended rapid diagnostic tests that can be performed with the existing instruments,measure
xdr,Drug resistance surveillance: Among pulmonary MDR-TB patients with drug susceptibility test results for any fluoroquinolone (FQ) and any second-line injectable agent (2LI) (variable mdr_dst_rlt): number with any resistance to both FQ and 2LI (i.e. XDR-TB in pre-2020 definitions),measure
xdr_coh,Outcomes for XDR-TB cases: cohort size,measure
xdr_died,Outcomes for XDR-TB cases: number died,measure
xdr_fail,Outcomes for XDR-TB cases: number whose treatment failed,measure
xdr_lost,Outcomes for XDR-TB cases: lost to follow-up,measure
xdr_succ,Outcomes for XDR-TB cases: treatment success (Cured or treatment completed),measure
xpert,Number of sites providing TB diagnostic services using Xpert MTB/RIF at the end of the reporting year,measure
xpert_eqa,Number of sites providing TB diagnostic services using Xpert MTB/RIF covered by a comprehensive EQA system,measure
xpert_etrans,Number of sites using Xpert MTB/RIF which transmit results automatically to clinicians and to an information management system,measure
zoonotic,(if ident_zoonotic=1) The number of people diagnosed with zoonotic TB,measure
cf_tot_sources,Total expected funding from all sources (US Dollars),string
iso15189_accredited,Number of sites with ISO15189 accreditation by the end of the reporting year,string
iso2,ISO 2-character country/territory code,string
iso3,ISO 3-character country/territory code,string
iso_numeric,ISO numeric country/territory code,string
name,Name,string
rcvd_tot_sources,Total funding received from all sources (US Dollars),string
source_hh,Source of estimate of average household size,string
source_rr_new,Method used to estimate proportion of new TB patients with rifampicin-resistant TB,string
source_rr_ret,Method used to estimate proportion of previously treated TB patients with rifampicin-resistant TB,string
year,Year,time
